Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT06017271

Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCTPA (computed tomography pulmonary angiography)The CTPA diagnosis suggest or did not suggest pulmonary embolism.

Timeline

Start date
2024-05-01
Primary completion
2024-07-15
Completion
2024-07-19
First posted
2023-08-30
Last updated
2024-07-22

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06017271. Inclusion in this directory is not an endorsement.